Background: Extracranial metastasis (EM) from glioblastoma (GB), IDH-wildtype (WHO CNS 2021 grade 4) is rare and often under-recognized, yet it has immediate implications for staging and management. We report a case series integrating advanced neuroimaging, whole-body imaging, and pathology/biomarkers to characterize imaging–pathology correlates of EM and highlight practical clinical triggers that should prompt systemic evaluation. Case presentation: We report three patients with adult-type, IDH-wildtype GB who developed EM confirmed by cytology/histology and/or concordant multimodality imaging. Brain MRI (1.5T/3T) demonstrated aggressive primary tumors with qualitative elevation of DSC-perfusion and frequent tumor–surface contact (dural, ependymal/leptomeningeal contact). Intratumoral susceptibility signal reached grade 3 where assessed. All patients underwent surgical resection followed by temozolomide-based chemoradiation; two received fotemustine and bevacizumab, and one underwent re-irradiation. EM presented with clinical triggers including severe axial/back pain, palpable cervical masses, and/or cytopenias. Initial EM sites were bone marrow/vertebrae (n = 1) and cervical lymph nodes (n = 2); staging revealed additional osseous disease in both nodal cases and a small pulmonary nodule in one. Nodal and osseous lesions were FDG-avid on 18F-FDG PET/CT. OLIG2-positive cytology confirmed cervical nodal metastases, and bone marrow aspiration with GFAP/OLIG2 positivity confirmed medullary infiltration. All tumors shared a molecular profile of TERT-promoter mutation, ATRX wild-type, TP53 mutation, and MGMT-promoter methylation. Despite attempts at second- and third-line therapies, disease progression was rapid, and all patients succumbed within 8–16 months of diagnosis. Discussion: This series underscores that EM can occur despite MGMT-promoter methylation and supports the concept of heterogeneous metastatic phenotypes in GB. Our cases reinforce that new axial/back pain or hematologic abnormalities may signal osseous or marrow involvement, and necrotic cervical lymphadenopathy in GB patients warrants dedicated imaging and tissue confirmation with glial markers. Integrating brain MRI features (high perfusion, surface contact, susceptibility burden) with FDG-PET/CT and targeted cytology/pathology can expedite diagnosis and inform multidisciplinary care. Conclusions: EM can arise despite MGMT-promoter methylation in IDH-wildtype GBM. Imaging red flags (high perfusion, surface contact, necrotic/FDG-avid cervical nodes) and clinical cues (axial pain, cytopenias, neck masses) should prompt early systemic staging (CT/PET-CT) and targeted tissue confirmation to advance management.
Purpose: Distinguishing radionecrosis (RN) from recurrent brain metastasis (rM1) remains a major challenge in the follow-up of patients treated with surgery and radiotherapy. Although advanced imaging techniques have been proposed to improve diagnostic accuracy, they are not always available in routine clinical practice and may be limited by postoperative changes and artifacts. Histopathologically validated studies in this setting remain scarce. Methods: We retrospectively evaluated 16 patients with 17 histologically confirmed lesions who underwent repeat surgery for suspected progression after the resection of brain metastases and adjuvant radiotherapy. Preoperative MRI examinations were reviewed by two neuroradiologists using a standard MRI protocol. Qualitative features included signal characteristics, T1/T2 mismatch, enhancement patterns, and the presence of the “inflammatory cloud” and “incomplete ring enhancement” signs. Quantitative analysis included lesion, edema and necrosis volumes, apparent diffusion coefficient (ADC), intratumoral susceptibility signal (ITSS) grading, and volumetric lesion quotient (vLQ). A LASSO logistic regression model with leave-one-out cross-validation and bootstrap stability analysis was used to identify the most relevant predictors. Results: Histopathology demonstrated 11 RN lesions and six recurrent metastases. The LASSO model achieved an area under the curve of 0.71 and an overall accuracy of 76% (13/17 lesions) with a sensitivity of 82% for RN and a specificity of 67% for rM1. RN lesions were characterized by significantly higher ADC values and ITSS grades and by the exclusive presence of the inflammatory cloud and incomplete ring enhancement signs. Stability analysis identified incomplete ring enhancement (49%), ITSS grade (45%), ADC values (45%), and inflammatory cloud (44%) as the most robust predictors of RN, whereas volumetric measurements showed limited independent predictive value. Conclusions: In patients with histologically confirmed post-treatment lesions, conventional MRI provided several reproducible features that aided differentiation between radionecrosis and recurrent brain metastasis. The inflammatory cloud, incomplete ring enhancement, elevated ADC values, and higher ITSS grades emerged as the most robust imaging markers of RN. While predictive multivariable models remain exploratory, these readily available MRI features may improve diagnostic confidence in routine clinical practice and warrant validation in larger multicenter cohorts.